Rate My Professor Aude Chapuis

Aude G. Chapuis, MD, is Associate Professor in the Translational Science and Therapeutics Division at Fred Hutchinson Cancer Center, where she holds the John C. and Karyl Kay Hughes Endowed Chair, and Associate Professor in the Department of Medicine, Division of Hematology and Oncology at the University of Washington. As an attending physician in the Medicine faculty at Fred Hutch Cancer Center, she serves on the Autologous and Allogeneic Transplant Services in the Bone Marrow Transplant Program. She treats patients with blood cancers, consults on stem cell transplantation, and cares for those receiving T-cell infusions in immunotherapy trials at the Bezos Family Immunotherapy Clinic. Dr. Chapuis earned her MD from Lausanne University in Switzerland in 1997. She completed pre-doctoral research fellowship and residency at the Laboratory of AIDS Immunopathogenesis, University Hospital Lausanne (1998-1999); residency at Cadolles Cantonal Hospital, Neuchâtel (2000-2001) and University Hospital Lausanne (2001-2003); postdoctoral fellowship at Fred Hutch (2003-2007); and medical oncology fellowship at Fred Hutch and University of Washington (2007-2010). She is certified by the Swiss Board of Internal Medicine.

The Chapuis laboratory develops TCR gene-engineered T cell immunotherapies via a translational pipeline encompassing target identification, TCR construct engineering, cell manufacturing, clinical trials, and immune monitoring. Projects target WT1 for acute myeloid leukemia and solid tumors, MAGE-A1 for non-small cell lung cancer, triple-negative breast cancer, bladder cancer, thoracic and gynecological cancers, and Merkel-cell polyoma virus antigens for Merkel cell carcinoma. She leads trials for leukemia, melanoma, Merkel cell carcinoma, lung cancer, mesothelioma, and breast cancer, sponsoring multiple INDs. Key publications include "T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant" (Nature Medicine, 2019), "Targeting an alternate Wilms' tumor antigen 1 peptide bypasses immunoproteasome dependency" (Science Translational Medicine, 2022), and "Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA" (Nature Communications, 2018). Her work improves T cell persistence and anti-tumor activity, advancing effective cancer immunotherapies.